Did UTHR advance TS Adcirca by dropping DPI R234?

[lakers]

United Therapeutics Looks To Develop Inhaled Adcirca - A Deeper Look
Mar. 13, 2019 7:46 PMUnited Therapeutics Corporation (UTHR)ARNA, LQDA, MNKD
Summary

It appears that the undisclosed compound in the deal between United Therapeutics and MannKind is Adcirca.
Adcirca is used to treat PAH.
Adcirca has the same active ingredient as Cialis.
When United Therapeutics (NASDAQ:UTHR) signed a deal with MannKind (MNKD) for a dry powder inhaled form of Treprostinil, the company also contracted an undisclosed compound within the PAH space. With United's most recent update of its pipeline page, it appears that the undisclosed compound is Adcirca.
www.google.com/amp/s/seekingalpha.com/amp/article/4248602-united-therapeutics-looks-develop-inhaled-adcirca-deeper-look

Respira Reacquires Full Rights Over RT234 for As-Needed PAH Symptom Relief
pulmonaryhypertensionnews.com/2019/10/14/respira-reacquires-full-rights-over-rt234-for-pah-symptom-relief/

This follows the decision of its partner United Therapeutics to terminate the collaboration with Respira, which was established in April 2017

RT234 is an inhaled therapy being developed to provide symptom relief in people with PAH. It is thought to help improve exercise tolerance and reduce breathlessness and fatigue related to PAH.

The therapeutic combo combines the potent vasodilator vardenafil — available in the United States in an oral form for the treatment of erectile dysfunction — with Respira’s dry-powder inhaler technology AOS-DPI. In contrast to available PAH therapies that are administrated under a specific treatment regimen, RT234 was designed to be taken when necessary (on-demand use).

In April, RT234 received orphan drug designation by the U.S. Food and Drug Administration for the treatment of PAH.

www.webmd.com/hypertension-high-blood-pressure/news/20090529/new-use-for-cialis-active-ingredient
Adcirca, which will be available in August, is made by the drug company Lilly, which also makes Cialis. Adcirca will be marketed in the U.S. by United Therapeutics Corporation.

The FDA approved Adcirca based on a clinical trial in which pulmonary arterial hypertension patients either took Adcirca (given as two daily tablets, with each tablet containing 20 milligrams of tadalafil) or a placebo pill for 16 weeks.

At the end of the study, the patients walked for six minutes; during that time, patients taking Adcirca walked 33 meters farther than patients in the placebo group. Patients taking Adcirca also had less clinical worsening of their pulmonary arterial hypertension during the study than patients taking the placebo, according to a news release from United Therapeutics.

[matt]

There are at least ten PDE5 inhibitors either on the market or in late stages of development, RT234 was one of the approved molecules and Adcirca is another. It is entirely possible that UTHR decided that vardenafil did not do the job well enough and opted to switch to tadalafil. PDE5 inhibitors have been around since the early 1990's but bioavailability from the oral forms has been a problem, something the new generation of drugs is designed to address. UTHR could be testing any of the late stage candidates for TS delivery.

[adventuresome]

any info out there on uthr milestone payment to mnkd